Literature DB >> 2975216

Factors involved in the pathogenesis of hypertensive cardiovascular hypertrophy. A review.

B Dahlöf1.   

Abstract

All tissues can rapidly adapt their structural design whenever prolonged changes of load/activity occur within the limits characteristic of each tissue. This structural adaptation, however, is modified by various genetic and trophic influences. When antihypertensive therapy is considered in the hypertensive patient, such changes are usually well established and the cardiovascular system is structurally adapted to maintain a higher pressure than normal. Increased blood pressure and afterload cannot solely explain the development of cardiac hypertrophy. Permissive actions from the sympathetic nervous system and the circulating angiotensin II are likely, but conflicting results still exist. There is evidence for a functional renin-angiotensin system in the heart, which may be involved in the genesis of left ventricular hypertrophy. Also, a soluble factor in the hypertrophied myocardium that stimulates protein synthesis may play a key role in modulation of myocardial structure during development or regression of myocardial hypertrophy in hypertension. Hypertrophy of both the large and smaller arterial vessels has been shown to follow the same general pattern of development and regression as in the heart. The vascular hypertrophy (predominantly of the media in the arterioles) can be considered as the ultimate structural factor behind the progression of hypertension independent of the initiating factor. A vicious circle with the increased resistance as the key factor can be identified. There are at least 3 possible initiating factors: a small rise in arterial pressure, an abnormal or reinforced response to pressure, or trophic/mitogenic stimuli acting directly on the vascular smooth muscle cell. The ultimate goal in the treatment of high blood pressure is to reduce hypertension-related morbidity and mortality. Normalisation of structural cardiovascular changes is also important and easier to evaluate in the individual. Understanding of the pathogenesis of structural adaptation may help in the selection of the best treatment.

Entities:  

Mesh:

Year:  1988        PMID: 2975216     DOI: 10.2165/00003495-198800355-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  190 in total

1.  Cardiac hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; P A Khairallah; F M Bumpus
Journal:  Circ Res       Date:  1974-11       Impact factor: 17.367

2.  Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; T Gordon; W P Castelli; J R Margolis
Journal:  Ann Intern Med       Date:  1970-06       Impact factor: 25.391

3.  Hemodynamics and other determinants in development of left ventricular hypertrophy.

Authors:  E D Frohlich
Journal:  Fed Proc       Date:  1983-07

4.  BP as a determinant of cardiac left ventricular muscle mass.

Authors:  J I Drayer; M A Weber; J L DeYoung
Journal:  Arch Intern Med       Date:  1983-01

5.  Peripheral large arteries and the response to antihypertensive treatment.

Authors:  M E Safar; J A Bouthier; J A Levenson; A C Simon
Journal:  Hypertension       Date:  1983 Sep-Oct       Impact factor: 10.190

Review 6.  Trophic effects of peripheral adrenergic nerves on vascular structure.

Authors:  R D Bevan
Journal:  Hypertension       Date:  1984 Nov-Dec       Impact factor: 10.190

7.  Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro.

Authors:  M Campbell-Boswell; A L Robertson
Journal:  Exp Mol Pathol       Date:  1981-10       Impact factor: 3.362

8.  What is the value of home blood pressure measurement in patients with mild hypertension?

Authors:  H D Kleinert; G A Harshfield; T G Pickering; R B Devereux; P A Sullivan; R M Marion; W K Mallory; J H Laragh
Journal:  Hypertension       Date:  1984 Jul-Aug       Impact factor: 10.190

9.  Circulatory and sympatho-adrenal responses to stress in borderline and established hypertension.

Authors:  K Eliasson; P Hjemdahl; T Kahan
Journal:  J Hypertens       Date:  1983-08       Impact factor: 4.844

Review 10.  Cardiac hypertrophy in early hypertension.

Authors:  Y Yamori; C Mori; T Nishio; A Ooshima; R Horie; M Ohtaka; T Soeda; M Saito; K Abe; Y Nara; Y Nakao; M Kihara
Journal:  Am J Cardiol       Date:  1979-10-22       Impact factor: 2.778

View more
  1 in total

Review 1.  Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy.

Authors:  C Morisco; L Argenziano; N Tozzi; A F Mele; B Ricciardelli; G Condorelli; B Trimarco
Journal:  Drugs       Date:  1993       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.